iSTAR Medical’s MINIject delivers exceptional 6-month results

Wavre, Belgium: 15 May 2018 - iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announced exceptional 6-month results of their first-in-human (FIH) micro-invasive glaucoma surgery (MIGS) trial for the MINIjectTM device in a standalone setting. Results show MINIject to be safe and highly effective in achieving significant intraocular pressure (IOP) reduction in glaucoma patients.

The trial showed that the implantation of MINIject resulted in an average 39% IOP reduction to a mean of 14.2 mmHg at six months. In addition, 87.5% of patients were able to discontinue topical medication usage and remained medication-free at six months. There were no serious ocular adverse events.

More info on iSTAR Medical's website.


Next > Nexstim Plc – first NBT® system for depression ordered in the US

Previous > Nexstim Plc launches NBT® system for depression at the US Clinical TMS Society Annual Meeting in New York